These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34127734)

  • 1. Higher cMET dependence of sacral compared to clival chordoma cells: contributing to a better understanding of cMET in chordoma.
    Lohberger B; Scheipl S; Heitzer E; Quehenberger F; de Jong D; Szuhai K; Liegl-Atzwanger B; Rinner B
    Sci Rep; 2021 Jun; 11(1):12466. PubMed ID: 34127734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug combination screening as a translational approach toward an improved drug therapy for chordoma.
    Scheipl S; Barnard M; Lohberger B; Zettl R; Brcic I; Liegl-Atzwanger B; Rinner B; Meindl C; Fröhlich E
    Cell Oncol (Dordr); 2021 Dec; 44(6):1231-1242. PubMed ID: 34550531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HOXA7, HOXA9, and HOXA10 are differentially expressed in clival and sacral chordomas.
    Jäger D; Barth TFE; Brüderlein S; Scheuerle A; Rinner B; von Witzleben A; Lechel A; Meyer P; Mayer-Steinacker R; Baer AV; Schultheiss M; Wirtz CR; Möller P; Mellert K
    Sci Rep; 2017 May; 7(1):2032. PubMed ID: 28515451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.
    van Veggel B; de Langen AJ; Hashemi S; Monkhorst K; Rosenberg EH; Heideman DAM; Radonic T; Smit EF
    Lung Cancer; 2018 Oct; 124():130-134. PubMed ID: 30268451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-dimensional lung tumor microenvironment modulates therapeutic compound responsiveness in vitro--implication for drug development.
    Ekert JE; Johnson K; Strake B; Pardinas J; Jarantow S; Perkinson R; Colter DC
    PLoS One; 2014; 9(3):e92248. PubMed ID: 24638075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UM-Chor1: establishment and characterization of the first validated clival chordoma cell line.
    Owen JH; Komarck CM; Wang AC; Abuzeid WM; Keep RF; McKean EL; Sullivan S; Fan X; Prince MEP
    J Neurosurg; 2018 Mar; 128(3):701-709. PubMed ID: 28430034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic landscape and ligand-dependent activation of sonic hedgehog-Gli1 signaling in chordomas: a novel therapeutic target.
    Yang C; Yong L; Liang C; Li Y; Ma Y; Wei F; Jiang L; Zhou H; He G; Pan X; Hai B; Wu J; Xu Y; Liu Z; Liu X
    Oncogene; 2020 Jun; 39(24):4711-4727. PubMed ID: 32404987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia.
    Kentsis A; Reed C; Rice KL; Sanda T; Rodig SJ; Tholouli E; Christie A; Valk PJ; Delwel R; Ngo V; Kutok JL; Dahlberg SE; Moreau LA; Byers RJ; Christensen JG; Vande Woude G; Licht JD; Kung AL; Staudt LM; Look AT
    Nat Med; 2012 Jul; 18(7):1118-22. PubMed ID: 22683780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration.
    Chattopadhyay C; Grimm EA; Woodman SE
    PLoS One; 2014; 9(2):e83957. PubMed ID: 24551032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma.
    Phan LM; Fuentes-Mattei E; Wu W; Velazquez-Torres G; Sircar K; Wood CG; Hai T; Jimenez C; Cote GJ; Ozsari L; Hofmann MC; Zheng S; Verhaak R; Pagliaro L; Cortez MA; Lee MH; Yeung SC; Habra MA
    Cancer Res; 2015 Oct; 75(19):4131-42. PubMed ID: 26282167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition.
    Megiorni F; McDowell HP; Camero S; Mannarino O; Ceccarelli S; Paiano M; Losty PD; Pizer B; Shukla R; Pizzuti A; Clerico A; Dominici C
    J Exp Clin Cancer Res; 2015 Oct; 34():112. PubMed ID: 26445453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
    Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
    Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying mechanisms for therapeutic intervention in chordoma: c-Met oncoprotein.
    Ostroumov E; Hunter CJ
    Spine (Phila Pa 1976); 2008 Dec; 33(25):2774-80. PubMed ID: 19050584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury.
    Magnaghi P; Salom B; Cozzi L; Amboldi N; Ballinari D; Tamborini E; Gasparri F; Montagnoli A; Raddrizzani L; Somaschini A; Bosotti R; Orrenius C; Bozzi F; Pilotti S; Galvani A; Sommer J; Stacchiotti S; Isacchi A
    Mol Cancer Ther; 2018 Mar; 17(3):603-613. PubMed ID: 29237806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.
    Nakade J; Takeuchi S; Nakagawa T; Ishikawa D; Sano T; Nanjo S; Yamada T; Ebi H; Zhao L; Yasumoto K; Matsumoto K; Yonekura K; Yano S
    J Thorac Oncol; 2014 Jun; 9(6):775-83. PubMed ID: 24828661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic inhibition of cell migration by tetraspanin CD82 and gangliosides occurs via the EGFR or cMet-activated Pl3K/Akt signalling pathway.
    Li Y; Huang X; Zhang J; Li Y; Ma K
    Int J Biochem Cell Biol; 2013 Nov; 45(11):2349-58. PubMed ID: 23968914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target.
    Ferrucci A; Moschetta M; Frassanito MA; Berardi S; Catacchio I; Ria R; Racanelli V; Caivano A; Solimando AG; Vergara D; Maffia M; Latorre D; Rizzello A; Zito A; Ditonno P; Maiorano E; Ribatti D; Vacca A
    Clin Cancer Res; 2014 Nov; 20(22):5796-807. PubMed ID: 25212607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of hepatocyte growth factor and c-MET in skull base chordoma.
    Naka T; Kuester D; Boltze C; Scheil-Bertram S; Samii A; Herold C; Ostertag H; Krueger S; Roessner A
    Cancer; 2008 Jan; 112(1):104-10. PubMed ID: 17948912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment and detailed functional and molecular genetic characterisation of a novel sacral chordoma cell line, MUG-Chor1.
    Rinner B; Froehlich EV; Buerger K; Knausz H; Lohberger B; Scheipl S; Fischer C; Leithner A; Guelly C; Trajanoski S; Szuhai K; Liegl B
    Int J Oncol; 2012 Feb; 40(2):443-51. PubMed ID: 22002331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crizotinib Fails to Enhance the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Xenografts.
    Baschnagel AM; Galoforo S; Thibodeau BJ; Ahmed S; Nirmal S; Akervall J; Wilson GD
    Anticancer Res; 2015 Nov; 35(11):5973-82. PubMed ID: 26504020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.